CD70 and acute myeloid leukemia: Preclinical studies have identified possible targets in acute myeloid leukaemia such as cells expressing CD70 and the CD70/CD27 signalling pathway, which were further tested in a phase I/II clinical trial using cusatuzumab—a human αCD70 monoclonal antibody exhibiting enhanced toxicity on leukemic stem cells with promising results [64].